# The impact of emerging *Plasmodium knowlesi* on accurate diagnosis by light microscopy: a systematic review and modelling analysis

John H. Huber*, Margaret Elliott, Cristian Koepfli, T. Alex Perkins

Department of Biological Sciences and Eck Institute for Global Health, University of Notre Dame, Notre Dame, IN, USA

Keywords: *Plasmodium knowlesi*; misdiagnosis; light microscopy; systematic review;

Word Count: 245 (Abstract); 2,660 (Main Text)

Figures: 4; Tables: 1; Supplementary Files: 1

Running Head: Misdiagnosis of malaria by microscopy

100 Galvin Life Sciences Center, Notre Dame, IN 46556; huber.j.h@wustl.edu

**ABSTRACT**

The five *Plasmodium* spp. that cause human malaria appear similar under light microscopy, which raises the possibility that misdiagnosis could routinely occur in clinical settings. Assessing the extent of misdiagnosis is of particular importance for monitoring *P. knowlesi*, which co-circulates with the other *Plasmodium* spp. We performed a systematic review and meta-analysis of studies comparing the performance of microscopy and PCR for diagnosing malaria in settings with co-circulation of the five *Plasmodium* spp. We assessed the extent to which co-circulation of *Plasmodium* parasites affects diagnostic outcomes. We fit a Bayesian hierarchical latent class model to estimate variation in microscopy sensitivity and specificity. Mean sensitivity of microscopy was low, yet highly variable across *Plasmodium* spp., ranging from 41.7% (95% CI: 22.8 – 64.1%) for *P. falciparum* and 40.3% (22.0 – 61.5%) for *P. vivax* to 0.119% (0.0121 – 0.640%) for *P. knowlesi*, 7.57% (2.66 – 22.0%) for *P. malariae*, and 0.180% (0.00491 – 1.21%) for *P. ovale.* Observed PCR prevalence was positively correlated with estimated microscopic sensitivity and negatively correlated with estimated microscopic specificity, though the strength of the associations varied by species. Our analysis suggests that co-circulation of *Plasmodium* spp. undermines the accuracy of microscopy. Sensitivity was considerably lower for *P. knowlesi*, *P. malariae*, and *P. ovale*. The negative association between specificity and prevalence imply that less frequently encountered species may be misdiagnosed as more frequently encountered species. Together, these results suggest that the burden of *P. knowlesi*, *P. malariae*, and *P. ovale* may be underappreciated in a clinical setting.

34 **INTRODUCTION**

35 *Plasmodium falciparum* and *Plasmodium vivax* are the predominant parasites responsible for
36 human malaria worldwide, causing an estimated 193.9 million and 14.3 million clinical cases in
37 2017, respectively[1,2]. Given their contribution to the global burden of malaria, *P. falciparum* and
38 *P. vivax* remain the primary focus of public health efforts aimed at achieving malaria elimination
39 and eradication[3]. However, three additional *Plasmodium* species—*P. knowlesi*, *P. malariae*, and
40 *P. ovale*—also cause clinical episodes of malaria, though their overall burden remains uncertain
41 due in part to routine misdiagnosis in a clinical setting[4].

42 Diagnosis of clinical malaria is routinely performed using light microscopy (LM). In
43 addition to challenges presented by low or submicroscopic parasite densities[5], accurate
44 speciation of malaria parasites using LM depends upon identification of morphological features
45 characteristic of the *Plasmodium* spp. causing the infection. However, morphological similarities
46 across the five *Plasmodium* spp., such as the resemblance of early blood-stage *P. knowlesi*
47 parasites to *P. falciparum* parasites and late blood-stage *P. knowlesi* parasites to *P. malariae*
48 parasites[3,6], undermine species-level identification of *Plasmodium* infections[7].

49 In settings with co-circulation of the *Plasmodium* spp., routine misdiagnosis by light
50 microscopy has consequences for clinical decision-making and malaria control. The choice of
51 therapeutic is specific to the *Plasmodium* spp. causing the infection[8], so misdiagnosis may lead
52 to ineffective treatment of blood-stage parasites for all *Plasmodium* spp. infections as well as
53 ineffective or no treatment of liver-stage parasites for *P. vivax* and *P. ovale* infections.
54 Additionally, misdiagnosis may present challenges for monitoring *Plasmodium* spp.
55 transmission, particularly for the emerging zoonosis *P. knowlesi*. Currently, the extent of human-

56 to-human transmission of *P. knowlesi* is unknown[3,9], and misdiagnosis could cause transmission
57 clusters to appear smaller than their actual size, leading to an underestimate of transmission[10].
58 Consequently, measuring the extent of misdiagnosis by light microscopy is of importance
59 to public health, and past studies have directly compared the diagnostic performance of light
60 microscopy to polymerase chain reaction (PCR) in settings with co-circulation of *Plasmodium*
61 spp. parasites[7,11–22]. However, these studies varied in their criteria for enrollment and other study
62 design features, as well as in the epidemiological settings in which they were conducted. This
63 makes direct comparison of their estimates of diagnostic performance challenging.
64 To synthesize across these studies, we performed a systematic review and meta-analysis
65 of the diagnostic performance of light microscopy in settings with co-circulation of all five
66 *Plasmodium* spp. We identified studies that compared the diagnostic performance of light
67 microscopy to PCR and fit a hierarchical Bayesian latent class model to estimate study-level and
68 species-level sensitivities and specificities of light microscopy. Finally, to assess whether the
69 perceived prevalences of the five species might affect diagnostic outcomes of light microscopy,
70 we explored the relationship between the estimates of sensitivity and specificity that we obtained
71 and the observed PCR prevalences in each study.
72
73 **METHODS**
74 **Search Strategy and Selection Criteria**
75 In this systematic review and meta-analysis, JHH searched MEDLINE and Web of Science for
76 studies published in English before April 30th, 2020 that compared the diagnostic performance of
77 light microscopy (LM) and polymerase chain reaction (PCR) for *Plasmodium* spp. infections.
78 We identified studies using the following search strategy: (*Plasmodium* OR malaria) AND

*knowlesi* AND ((microscopy OR microscopic OR blood film OR thick film OR thin film) AND (PCR or "polymerase chain reaction")).

Studies met the criteria for inclusion if they compared the performance of LM and PCR on clinical samples collected in areas with endemic transmission of all five *Plasmodium* spp. that naturally infect humans (i.e., *P. falciparum*, *P. vivax*, *P. knowlesi*, *P. malariae*, and *P. ovale*). Furthermore, studies were only included if they used a PCR protocol that was capable of amplifying DNA from all five *Plasmodium* spp. Prior to 2004, the public health burden of *P. knowlesi* was underappreciated[6], so restricting our search to studies published between 2004 and 2021 ensured that the diagnostic outcomes were representative of the current clinical and diagnostic landscape.

The data were extracted from each study that met the criteria for inclusion. Because the data in each study was anonymized and reported in aggregate, ethical approvals were not required according to a determination from the University of Notre Dame Institutional Review Board that this study did not constitute human subjects research.

## Data Analysis

### *Overview*

To model the diagnostic performance of LM and PCR, we constructed a Bayesian hierarchical latent class model of clinical diagnosis[23]. In this model, the probability $p_{ijkl}$ of obtaining LM outcome $i \in \{1,0\}$ and PCR outcome $j \in \{1,0\}$ for *Plasmodium* spp. $k$ in study $l$ is

100 $$p_{ijkl} = \begin{cases} se_{LM}^{(k,l)} se_{PCR}^{(k,l)} \theta_k^{(l)} + \left(1 - sp_{LM}^{(k,l)}\right)\left(1 - sp_{PCR}^{(k,l)}\right)\left(1 - \theta_k^{(l)}\right), & i = 1, j = 1 \\ se_{LM}^{(k,l)}\left(1 - se_{PCR}^{(k,l)}\right)\theta_k^{(l)} + \left(1 - sp_{LM}^{(k,l)}\right) sp_{PCR}^{(k,l)}\left(1 - \theta_k^{(l)}\right), & i = 1, j = 0 \\ \left(1 - se_{LM}^{(k,l)}\right) se_{PCR}^{(k,l)} \theta_k^{(l)} + sp_{LM}^{(k,l)}\left(1 - sp_{PCR}^{(k,l)}\right)\left(1 - \theta_k^{(l)}\right), & i = 0, j = 0 \\ \left(1 - se_{LM}^{(k,l)}\right)\left(1 - se_{PCR}^{(k,l)}\right)\theta_k^{(l)} + sp_{LM}^{(k,l)} sp_{PCR}^{(k,l)}\left(1 - \theta_k^{(l)}\right), & i = 0, j = 0 \end{cases}. \quad (1)$$

101

102 In eq. (1), $se_{LM}^{(k,l)}$ and $sp_{LM}^{(k,l)}$ are the sensitivity and specificity of LM for *Plasmodium* spp. $k$ in
103 study $l$, $se_{PCR}^{(k,l)}$ and $sp_{PCR}^{(k,l)}$ are the sensitivity and specificity of PCR for *Plasmodium* spp. $k$ in
104 study $l$, and $\theta_k^{(l)}$ is the prevalence of *Plasmodium* spp. $k$ among participants in study $l$. In many
105 cases, $\theta_k^{(l)}$ is not equivalent to community prevalence, due to characteristics of the study
106 participants that are not representative of the surrounding community.

107 A key assumption of the latent class model is that diagnostic outcomes are conditionally
108 independent. That is, by assuming that the sensitivity and specificity of a given diagnostic
109 method is unique for each *Plasmodium* spp., the outcome that we observe for one parasite
110 species using a given diagnostic method is modelled as independent of the outcomes observed
111 for all other parasite species and diagnostic methods. This implies that the probability of a set of
112 diagnostic outcomes observed across all five *Plasmodium* spp. is equal to the product of the
113 probabilities of the diagnostic outcome for each *Plasmodium* spp. Nevertheless, the assumption
114 of conditional independence still allows for interactions between *Plasmodium* spp. that arise in
115 the context of misdiagnosis. For example, if a *P. knowlesi* infection is misdiagnosed as a *P.*
116 *malariae* infection using LM, then the sensitivity of LM for *P. knowlesi* and the specificity of
117 LM for *P. malariae* are penalized, because both a false-negative *P. knowlesi* diagnosis and a
118 false-positive *P. malariae* diagnosis occurred.

119

120 ***Accounting for Differences in Study Design***

121 Studies identified in the systematic review varied by enrollment and diagnostic criteria. Where
122 enrollment in a study required a positive *Plasmodium* spp. diagnosis by LM or PCR, we
123 normalized the probabilities of eq. (1), such that they were consistent with the subset of possible
124 diagnostic outcomes that could be observed with that study design.

125 Because *P. knowlesi* and *P. malariae* share morphological similarities[3,6], studies may
126 diagnose samples as "*P. knowlesi* / *P. malariae*" with LM, indicating that the microscopist
127 identified *P. knowlesi* and/or *P. malariae* parasites in the sample but could not make a more
128 precise mono-infection or co-infection diagnosis. To accommodate this in our model, we defined
129 parameters $se_{LM}^{("Pk/Pm"|Pk,l)}$ and $se_{LM}^{("Pk/Pm"|Pm,l)}$ as the sensitivities of LM to diagnose samples in
130 study $l$ as "*P. knowlesi* / *P. malariae*", given that the samples contained *P. knowlesi* and *P.*
131 *malariae* parasites, respectively.

132

133 ***Inference***

134 Using PCR as the gold standard, we fit a hierarchical latent class model of clinical diagnosis to
135 the studies identified in our systematic review to estimate study-level and species-level variation
136 in LM sensitivity and specificity for each *Plasmodium* spp. We fit our model in a Bayesian
137 framework using Stan by running four independent chains of 2,000 samples, each with a warm-
138 up period of 1,000 samples[24]. We tested for convergence with the Gelman-Rubin statistic and
139 pooled the independent chains for a posterior distribution of 4,000 samples. Supplementary
140 analyses were performed to evaluate the sensitivity of our posterior estimates to the inclusion of
141 each study and to the assumption of PCR as the gold standard. See the Supporting Information
142 for more details.

143

144 **RESULTS**

145 Of the 176 unique studies identified using MEDLINE and Web of Science, 12 studies met the
146 inclusion criteria, and their data comparing LM and PCR diagnostic performance were extracted
147 (Fig. 1). The studies enrolled febrile patients presenting in health clinics in Malaysia (n = 7),
148 Thailand (n = 2), Indonesia (n = 1), Myanmar (n = 1), and China (n = 1). Among the 12,690 total
149 patients enrolled across the 12 studies, the pooled percentage positive by PCR was 17% for *P.*
150 *falciparum*, 24% for *P. vivax*, 38% for *P. knowlesi*, 1.7% for *P. malariae*, and 0.36% for *P. ovale*
151 (Table 1). The studies varied widely in the percentage positive by PCR across *Plasmodium* spp.,
152 encompassing a wide range of epidemiological settings and study designs (i.e., criteria for patient
153 enrollment) in which we estimated LM diagnostic performance.

154




***Figure 1. PRISMA Flow Diagram.*** *Flow diagram of the studies identified using MEDLINE and Web of Science for the systematic review.*

160 ***Table 1. Reported Plasmodium spp. percentage positive by diagnostic method.*** *The percentage*
161 *of study participants positive by LM and PCR are reported for each Plasmodium spp. in each*
162 *study, along with the study location, year, and total number and type of samples collected. For*
163 *Pk and Pm LM percentage of study participants positive, * indicates that the percentage positive*
164 *was computed using a diagnosis of "Pk/Pm."*

| Ref. | Location | Samples | Type | Years | *P. falciparum* | | *P. vivax* | | *P. knowlesi* | | *P. malariae* | | *P. ovale* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | *PCR* | *LM* | *PCR* | *LM* | *PCR* | *LM* | *PCR* | *LM* | *PCR* | *LM* |
| [15] | Malaysia | 960 | LM+ | 2001-2006 | 26 (249) | 23 (218) | 51 (487) | 45 (430) | 28 (266) | 0.0 (0) | 0.42 (4) | 33 (312) | 0.73 (7) | 0.21 (2) |
| [19] | Thailand | 1,874 | Any Febrile | 2006-2007 | 41 (762) | 37 (687) | 64 (1192) | 54 (1021) | 0.53 (10) | 0.0 (0) | 1.3 (24) | 0.16 (3) | 0.96 (18) | 0.0 (0) |
| [16] | Malaysia | 189 | LM+ | 2008-2011 | 37 (70) | 39 (74) | 35 (66) | 35 (67) | 22 (42) | 0.0 (0) | 1.1 (2) | 27 (51) | 0.0 (0) | 0.0 (0) |
| [11] | Malaysia | 461 | LM+ | 2009-2011 | 7.2 (33) | 12 (54) | 16 (74) | 13 (59) | 85 (392) | 92* (425) | 0.87 (4) | 2* (425) | 0.0 (0) | 0.0 (0) |
| [13] | Malaysia | 227 | Any Febrile | 2008-2010 | 42 (95) | 41 (92) | 41 (92) | 38 (87) | 16 (36) | 0.0 (0) | 0.88 (2) | 15 (33) | 0.044 (1) | 0.044 (1) |
| [21] | China | 560 | Any Febrile | 2008-2012 | 28 (159) | 28 (156) | 51 (288) | 49 (276) | 0.36 (2) | 0.0 (0) | 1.6 (9) | 0.0 (0) | 2.7 (15) | 0.0 (0) |
| [7] | Malaysia | 303 | PCR+/LM+ | 2010-2011 | 43 (130) | 47 (142) | 16 (47) | 16 (47) | 44 (132) | 42* (128) | 0.66 (2) | 42* (128) | 0.0 (0) | 0.0 (0) |
| [12] | Thailand | 297 | Any Febrile | 2012 | 9.1 (27) | 3.4 (10) | 8.8 (26) | 5.1 (15) | 0.0 (0) | 0.0 (0) | 0.34 (1) | 0.34 (1) | 0.0 (0) | 0.0 (0) |
| [20] | Malaysia | 457 | LM+ | 2012-2013 | 11 (51) | 12 (54) | 32 (144) | 30 (138) | 58 (267) | 40 (185) | 0.22 (1) | 18 (81) | 0.044 (2) | 0.022 (1) |
| [17] | Myanmar | 90 | Any Febrile | 2013-2015 | 44 (40) | 43 (39) | 20 (18) | 19 (17) | 0.0 (0) | 0.0 (0) | 1.1 (1) | 1.1 (1) | 0.0 (0) | 0.0 (0) |
| [18] | Indonesia | | Any Febrile | 2015 | | | | | | | | | | |
| | *Batubara* | 1,270 | | | 6.2 (79) | 3.4 (43) | 10 (131) | 6.5 (83) | 12 (148) | 0.0 (0) | 1.2 (15) | 0.0 (0) | 0.0 (0) | 0.0 (0) |
| | *Langkat* | 544 | | | 16 (87) | 9.6 (52) | 16 (85) | 10 (56) | 5.9 (32) | 0.0 (0) | 1.1 (6) | 0.18 (1) | 0.0 (0) | 0.0 (0) |
| | *South Nias* | 1,917 | | | 12 (227) | 15 (294) | 17 (321) | 6.8 (131) | 14 (263) | 0.0 (0) | 5.6 (107) | 0.0 (0) | 0.0 (0) | 0.0 (0) |

| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| [14] | Malaysia | 3,541 | PCR+/LM+ | 2015-2017 | 4.9 (173) | 4.9 (174) | 2.5 (87) | 2.5 (87) | 92 (3255) | 93* (3280) | 1.1 (40) | 93* (3280) | 0.085 (3) | 0.0 (0) |
| **Total** | | 12,690 | | | 17 (2182) | 16 (2089) | 24 (3058) | 20 (2514) | 38 (4845) | 32 (4018) | 1.7 (218) | 34 (4316) | 0.36 (46) | 0.032 (4) |

165

166

167 After validating on 200 simulated datasets (Fig. S1), we applied our hierarchical latent class
168 model to the data from the 12 studies identified in the systematic review. Our fitted hierarchical
169 latent class model captured the variation in the observed data (Fig. S2) and revealed differences
170 in LM diagnostic performance across *Plasmodium* spp. (Fig. 2). Specifically, we estimated that
171 the species-level mean sensitivity of LM was 41.7% (95% CI: 22.8 – 64.1%) for *P. falciparum*,
172 40.3% (22.0 – 61.5%) for *P. vivax*, 0.119% (0.0121 – 0.640%) for *P. knowlesi*, 7.57% (2.66 –
173 22.0%) for *P. malariae*, and 0.180% (0.00491 – 1.21%) for *P. ovale*. Species-level mean
174 specificity of LM was consistently high across *Plasmodium* spp. and was estimated at 98.5%
175 (96.7 – 99.4%) for *P. falciparum*, 98.8% (97.3 – 99.5%) for *P. vivax*, 100% (99.9 – 100%) for *P.*
176 *knowlesi*, 99.3% (98.0 – 99.8%) for *P. malariae*, and 100% (100 – 100%) for *P. ovale*. These
177 results were robust to the assumption of PCR as the gold standard (Fig. S4).
178




***Figure 2. Group-level posterior estimates of LM diagnostic performance.*** *The group-level distributions of LM sensitivity (A, C, E, G, I) and LM specificity (B, D, F, H, I) are shown for*

182 *Plasmodium falciparum (teal; A, B), Plasmodium vivax (orange; C, D), Plasmodium knowlesi*
183 *(purple; E, F), Plasmodium malariae (pink; G, H), and Plasmodium ovale (green; I, J). Thick*
184 *lines are the maximum a posteriori estimates, and thin lines are 25 posterior samples.*
185
186 The variance in the hierarchical distributions of LM diagnostic performance in Fig. 2 revealed
187 the extent of variation across studies, a feature that depended upon both the diagnostic measure
188 and the *Plasmodium* spp. considered (Fig. 3). In general, for a given *Plasmodium* spp., we
189 estimated greater variation across studies in LM sensitivity than specificity. For example, for *P.*
190 *falciparum*, we estimated that logit-transformed standard deviation of LM sensitivity was 1.61
191 (1.26 – 2.09), suggesting that the range of sensitivities that fell within one standard deviation of
192 the mean was 12.5 – 78.2%. By comparison, the estimated logit-transformed standard deviation
193 of LM specificity for *P. falciparum* was 1.48 (1.13 – 1.93), corresponding to a range of
194 specificities within one standard deviation of the mean of 93.8 – 99.7%. Across *Plasmodium*
195 spp., study-level estimates of LM sensitivity and specificity for *P. falciparum*, *P. vivax*, and *P.*
196 *malariae* exhibited greater variation than for *P. knowlesi* and *P. ovale.*
197




198

199 ***Figure 3. Site-level posterior estimates of LM diagnostic performance.*** *The site-level posterior*

200 *estimates of (A) LM sensitivity and (B) LM specificity are shown for P. falciparum (teal), P.*

201 *vivax (orange), P. knowlesi (purple), P. malariae (pink), and P. ovale (green). Circles are the*
202 *median posterior estimate, and the vertical segment is the 95% credible interval. The horizontal*
203 *line is the posterior median of the group-level mean, and the horizontal shaded region is the*
204 *corresponding 95% credible interval.*
205
206 Because the estimates of LM diagnostic performance varied across the unique studies, we then
207 assessed its relationship with observed PCR prevalence (Fig. 4). We observed strong, positive
208 correlations between PCR prevalence and LM sensitivity for *P. falciparum* (Pearson Correlation
209 Test: $\rho = 0.66$; $p = 0.01$) and *P. knowlesi* ($\rho = 0.83$; $p = 0.0015$) and weaker, positive correlations
210 for *P. vivax* ($\rho = 0.40$) and *P. ovale* ($\rho = 0.012$), though the latter two were not statistically
211 significant associations. By contrast, for *P. malariae*, there was a negative correlation between
212 PCR prevalence and LM sensitivity, though this estimate was also not statistically significant.
213 Across *Plasmodium* spp., increased PCR prevalence of *P. knowlesi* was associated with reduced
214 sensitivity of LM for *P. vivax* ($\rho = -0.58$; $p = 0.029$), highlighting a possible source of
215 misdiagnosis. Additional negative associations were observed between PCR prevalence and LM
216 sensitivity across *P. falciparum*, *P. knowlesi*, and *P. malariae—Plasmodium* spp. that are
217 commonly misdiagnosed—though these quantities were not statistically significant.
218 Generally, for a given *Plasmodium* spp., PCR prevalence was negatively associated with
219 LM specificity (Fig. 4B). For *P. knowlesi*, this association was strong and statistically significant
220 ($\rho = -0.62$; $p = 0.017$), and additional weaker, yet statistically non-significant relationships were
221 observed for *P. falciparum*, *P. vivax*, and *P. ovale*. The opposite relationship was observed for *P.*
222 *malariae,* though this quantity was not statistically significant. Across *Plasmodium* spp.,
223 increased prevalence of *P. malariae* was associated with reduced specificities of LM for *P.*

224 *falciparum* (ρ = -0.79; p < 0.001) and *P. vivax* (ρ = -0.72; p = 0.0036), and increased prevalence

225 of *P. knowlesi* was associated with reduced specificity of LM for *P. malariae*.

226




227

228 ***Figure 4. Correlations between Plasmodium spp. fever prevalence and LM diagnostic***

229 ***performance.*** *The correlations between Plasmodium spp. fever prevalence and (A) LM*

230 *sensitivity and (B) LM specificity are reported. The color represents the strength of the*

231 *correlation, with red colors denoting positive correlations and blue colors denoting negative*

232 *correlations. '*' denotes p < 0.05, '**' denotes p < 0.01, and '***' denotes p < 0.001.*

233

234 **DISCUSSION**

235 In this systematic review and meta-analysis, we estimated study-level and species-level variation

236 in the malaria diagnostic performance of light microscopy in epidemiological settings with co-

237 circulation of the five *Plasmodium* spp. that cause human malaria. Our analysis revealed

238 consistently low sensitivity of light microscopy to diagnose *Plasmodium* spp. infection.

239 Sensitivity of light microscopy was estimated to be considerably lower for *P. knowlesi*, *P.*

240 *malariae*, and *P. ovale* than for *P. falciparum* and *P. vivax*. This suggests that the burden of *P.*

241 *knowlesi*, *P. malariae*, and *P. ovale* in a clinical setting may be appreciably underestimated,
242 consistent with a recent study of *P. ovale* in health clinics in Kenya[4].
243 Post-hoc analyses revealed relationships between the diagnostic performance of light
244 microscopy and the epidemiological setting. In general, we noted a positive association between
245 the PCR prevalence of a *Plasmodium* spp. and the sensitivity of light microscopy for that
246 *Plasmodium* spp. This supports a phenomenon whereby the more a microscopist encounters
247 samples of a *Plasmodium* spp. infection in a clinical setting, the more likely they are to
248 accurately identify the *Plasmodium* spp. causing that infection. By contrast, increased PCR
249 prevalence of a *Plasmodium* spp. was associated with high false-positive probabilities for that
250 *Plasmodium* spp. This tendency to misdiagnose malaria infections as what is most commonly
251 encountered in that clinical setting could lead to ineffective monitoring of less commonly
252 encountered *Plasmodium* spp., such as *P. knowlesi*, *P. malariae*, *and P. ovale.*
253 The high probabilities of misdiagnosis estimated in this analysis could have important
254 consequences for malaria treatment and control. Specifically, we observed an association
255 between increased prevalence of *P. knowlesi* and reduced sensitivity of LM for *P. vivax*. This
256 suggests that in areas with *P. knowlesi*, infections of *P. vivax* may not be correctly diagnosed and
257 therefore may not receive radical cure therapy to clear hypnozoites and prevent relapse[25].
258 Additionally, increased prevalence of *P. malariae* was associated with reduced specificity of LM
259 for *P. vivax*, indicating that many *P. malariae* infections may be misdiagnosed as *P. vivax*. This
260 form of misdiagnosis could unnecessarily subject individuals to radical cure therapy, potentially
261 increasing the risk of acute hemolysis among individuals deficient of the glucose-6-phosphate
262 dehydrogenase enzyme[26].

263 Routine diagnosis of clinical malaria by light microscopy may prevent effective
264 monitoring of *P. knowlesi* transmission and burden. We estimated very low sensitivity of LM to
265 diagnose *P. knowlesi* infections, given the morphological similarities of the parasites to those of
266 *P. falciparum* and *P. malariae*[3,6] as well as likely delays in familiarity of *P. knowlesi* among
267 microscopists in the health systems. Sensitivity of LM was improved in settings that allowed for
268 a "*P. knowlesi/P. malariae*" diagnosis, indicating that further speciation is often not possible.
269 Although in practice *P. knowlesi* and *P. malariae* infections diagnosed by light microscopy are
270 confirmed by PCR in many settings[11], *P. knowlesi* infections misdiagnosed as *P. falciparum*, for
271 instance, would not be subject to confirmatory PCR. This could lead to an underestimate of *P.*
272 *knowlesi* burden, affecting epidemiological assessments of *P. knowlesi* infection risk.
273 Our analysis is subject to a number of limitations. Our systematic review may not have
274 identified all studies with relevant data, including those studies not indexed by MEDLINE and
275 Web of Science. We limited our review to studies that tested for all five *Plasmodium* spp.
276 However, studies that included subsets of the five *Plasmodium* spp. could still be informative of
277 species-level diagnostic performance. Our latent class model assumed conditional independence
278 of diagnosis across *Plasmodium* spp. Future extensions of this work could account for the
279 correlation structure of LM diagnosis across the *Plasmodium* spp., due to shared morphologies of
280 the parasites. Additionally, to address non-identifiability issues, we assumed PCR to be the gold
281 standard. Although sensitivity analyses revealed that our species-level estimates were robust to
282 this assumption, future work could jointly estimate the diagnostic performance of both methods,
283 providing a more complete characterization of misdiagnosis of *Plasmodium* spp. in settings with
284 co-circulation of multiple *Plasmodium* species.
285

286 **NOTES**

287 ***Acknowledgments***

288 The authors thank Parker Ladwig for helpful advice on conducting a systematic review.

289

290 ***Author Contributions***

291 J.H.H. and T.A.P. conceived of the study. J.H.H. developed the methodology and performed the
292 systematic review and analyses. J.H.H. and M.E. verified the underlying data. J.H.H., M.E.,
293 C.K., and T.A.P. interpreted the results. J.H.H. and T.A.P. wrote the initial draft, and all authors
294 provided comments on the final draft. All authors had access to the underlying data.

295

296 ***Disclaimer***

297 The funding sources had no role in the study design, data collection, analysis, interpretation, or
298 writing of the report.

299

300 ***Financial Support***

301 This work was supported by a Graduate Research Fellowship from the National Science
302 Foundation to J.H.H, a Richard and Peggy Notebaert Premier Fellowship from the University of
303 Notre Dame to J.H.H, the National Institute of General Medical Sciences [grant number
304 1R35GM143029-01] to T.A.P, and the National Institute of Allergy and Infectious Diseases
305 [grant number R21-AI137891] to C.K.

306

307 ***Potential Conflicts of Interest***

308 All authors have no conflicts of interest to declare.

***Availability of Data and Materials***

All code and data to reproduce the analyses can be accessed at https://github.com/johnhhuber/malaria_misdiagonsis.git.

***Co-Author Contact Information***

Margaret Elliott: Department of Biological Sciences, 100 Galvin Life Sciences Center, Notre Dame, IN, USA 46556; melliot5@nd.edu

Cristian Koepfli: Department of Biological Sciences, 100 Galvin Life Sciences Center, Notre Dame, IN, USA 46556; ckoepfli@nd.edu

T. Alex Perkins: Department of Biological Sciences, 100 Galvin Life Sciences Center, Notre Dame, IN, USA 46556; taperkins@nd.edu

**REFERENCES**

1. Weiss DJ, Lucas TCD, Nguyen M, Nandi AK, Bisanzio D, Battle KE, Cameron E, Twohig KA, Pfeffer DA, Rozier JA, Gibson HS, Rao PC, Casey D, Bertozzi-Villa A, Collins EL, et al., 2019. Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum, 2000–17: a spatial and temporal modelling study. *The Lancet 394*: 322–331
2. Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, Pfeffer DA, Cameron E, Rao PC, Casey D, Gibson HS, Rozier JA, Dalrymple U, Keddie SH, Collins EL, et al., 2019.

331 Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and
332 temporal modelling study. *The Lancet 394*: 332–343
333 3. Feachem RGA, Chen I, Akbari O, Bertozzi-Villa A, Bhatt S, Binka F, Boni MF, Buckee C,
334 Dieleman J, Dondorp A, Eapen A, Sekhri Feachem N, Filler S, Gething P, Gosling R, et al.,
335 2019. Malaria eradication within a generation: ambitious, achievable, and necessary. *The Lancet*
336 *394*: 1056–1112
337 4. Akala HM, Watson OJ, Mitei KK, Juma DW, Verity R, Ingasia LA, Opot BH, Okoth RO,
338 Chemwor GC, Juma JA, Mwakio EW, Brazeau N, Cheruiyot AC, Yeda RA, Maraka MN, et al.,
339 2021. Plasmodium interspecies interactions during a period of increasing prevalence of
340 Plasmodium ovale in symptomatic individuals seeking treatment: an observational study. *The*
341 *Lancet Microbe 2*: e141–e150
342 5. Whittaker C, Slater H, Nash R, Bousema T, Drakeley C, Ghani AC, Okell LC., 2021. Global
343 patterns of submicroscopic Plasmodium falciparum malaria infection: insights from a systematic
344 review and meta-analysis of population surveys. *The Lancet Microbe*: S2666524721000550
345 6. Singh B, Sung LK, Matusop A, Radhakrishnan A, Shamsul SS, Cox-Singh J, Thomas A,
346 Conway DJ., 2004. A large focus of naturally acquired Plasmodium knowlesi infections in
347 human beings. *The Lancet 363*: 1017–1024
348 7. Barber BE, William T, Grigg MJ, Yeo TW, Anstey NM., 2013. Limitations of microscopy to
349 differentiate Plasmodium species in a region co-endemic for Plasmodium falciparum,
350 Plasmodium vivax and Plasmodium knowlesi. *Malar J 12*: 8
351 8. Anon., 2015. *Guidelines for the Treatment of Malaria*. 3rd ed. Geneva: World Health
352 Organization

9. Kantele A, Jokiranta TS., 2011. Review of cases with the emerging fifth human malaria parasite, Plasmodium knowlesi. *Clin Infect Dis 52*: 1356–1362

10. Blumberg S, Lloyd-Smith JO., 2013. Comparing methods for estimating R0 from the size distribution of subcritical transmission chains. *Epidemics 5*: 131–145

11. Barber BE, William T, Dhararaj P, Anderios F, Grigg MJ, Yeo TW, Anstey NM., 2012. Epidemiology of Plasmodium knowlesi malaria in north-east Sabah, Malaysia: family clusters and wide age distribution. *Malar J 11*: 401

12. Baum E, Sattabongkot J, Sirichaisinthop J, Kiattibutr K, Jain A, Taghavian O, Lee M-C, Huw Davies D, Cui L, Felgner PL, Yan G., 2016. Common asymptomatic and submicroscopic malaria infections in Western Thailand revealed in longitudinal molecular and serological studies: a challenge to malaria elimination. *Malar J 15*: 333

13. Chua KH, Lim SC, Ng CC, Lee PC, Lim YAL, Lau TP, Chai HC., 2015. Development of High Resolution Melting Analysis for the Diagnosis of Human Malaria. *Scientific Reports 5*: 15671

14. Cooper DJ, Rajahram GS, William T, Jelip J, Mohammad R, Benedict J, Alaza DA, Malacova E, Yeo TW, Grigg MJ, Anstey NM, Barber BE., 2020. Plasmodium knowlesi Malaria in Sabah, Malaysia, 2015-2017: Ongoing Increase in Incidence Despite Near-elimination of the Human-only Plasmodium Species. *Clin Infect Dis 70*: 361–367

15. Cox-Singh J, Davis TME, Lee K-S, Shamsul SSG, Matusop A, Ratnam S, Rahman HA, Conway DJ, Singh B., 2008. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. *Clin Infect Dis 46*: 165–171

16. Goh XT, Lim YAL, Vythilingam I, Chew CH, Lee PC, Ngui R, Tan TC, Yap NJ, Nissapatorn V, Chua KH., 2013. Increased detection of Plasmodium knowlesi in Sandakan division, Sabah as revealed by PlasmoNex$^{TM}$. *Malar J 12*: 264

17. Han TZ, Han KT, Aye KH, Hlaing T, Thant KZ, Vythilingam I., 2017. Comparison of microscopy and PCR for the detection of human Plasmodium species and Plasmodium knowlesi in southern Myanmar. *Asian Pacific Journal of Tropical Biomedicine 7*: 680–685

18. Lubis IND, Wijaya H, Lubis M, Lubis CP, Divis PCS, Beshir KB, Sutherland CJ., 2017. Contribution of Plasmodium knowlesi to Multispecies Human Malaria Infections in North Sumatera, Indonesia. *J Infect Dis 215*: 1148–1155

19. Putaporntip C, Hongsrimuang T, Seethamchai S, Kobasa T, Limkittikul K, Cui L, Jongwutiwes S., 2009. Differential prevalence of Plasmodium infections and cryptic Plasmodium knowlesi malaria in humans in Thailand. *J Infect Dis 199*: 1143–1150

20. Yusof R, Lau YL, Mahmud R, Fong MY, Jelip J, Ngian HU, Mustakim S, Hussin HM, Marzuki N, Mohd Ali M., 2014. High proportion of knowlesi malaria in recent malaria cases in Malaysia. *Malar J 13*: 168

21. Zhou X, Huang J-L, Njuabe MT, Li S-G, Chen J-H, Zhou X-N., 2014. A molecular survey of febrile cases in malaria-endemic areas along China-Myanmar border in Yunnan province, People's Republic of China. *Parasite 21*: 27

22. Rahim MAFA, Munajat MB, Idris ZM., 2020. Malaria distribution and performance of malaria diagnostic methods in Malaysia (1980-2019): a systematic review. *Malar J 19*: 395

23. Gonçalves L, Subtil A, de Oliveira MR, do Rosário V, Lee P-W, Shaio M-F., 2012. Bayesian Latent Class Models in Malaria Diagnosis. *PLoS ONE 7*: e40633

24. Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, Brubaker M, Guo J, Li P, Riddell A., 2017. *Stan* : A Probabilistic Programming Language. *J Stat Soft 76*

397 75. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA., 2009.
398 Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. *The*
399 *Lancet Infectious Diseases 9*: 555–566
400 76. Baird JK, Battle KE, Howes RE., 2018. Primaquine ineligibility in anti-relapse therapy of
401 Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6
402 polymorphisms. *Malar J 17*: 42, s12936-018-2190-z
403